147 related articles for article (PubMed ID: 21622187)
41. [Basic carboxypeptidases of blood: significance for coagulology].
Timofeev АV
Biomed Khim; 2016; 62(2):141-9. PubMed ID: 27143370
[TBL] [Abstract][Full Text] [Related]
42. Atorvastatin downregulates plasma procarboxypeptidase U concentrations and improves fibrinolytic potential dose-dependently in hyperlipidemic individuals.
Claesen K; Sim Y; Basir S; De Belder S; van den Keybus T; Van Edom G; Stoffelen H; De Keulenaer GW; Bosmans J; Bringmans T; De Meester I; Hendriks D
J Thromb Haemost; 2023 May; 21(5):1266-1273. PubMed ID: 36740042
[TBL] [Abstract][Full Text] [Related]
43. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma.
Broze GJ; Higuchi DA
Blood; 1996 Nov; 88(10):3815-23. PubMed ID: 8916945
[TBL] [Abstract][Full Text] [Related]
44. Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin.
Valnickova Z; Enghild JJ
J Biol Chem; 1998 Oct; 273(42):27220-4. PubMed ID: 9765243
[TBL] [Abstract][Full Text] [Related]
45. Fast homogeneous assay for plasma procarboxypeptidase U.
Schatteman KA; Goossens FJ; Leurs J; Kasahara Y; Scharpé SS; Hendriks DF
Clin Chem Lab Med; 2001 Sep; 39(9):806-10. PubMed ID: 11601677
[TBL] [Abstract][Full Text] [Related]
46. Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase.
Valnickova Z; Thøgersen IB; Potempa J; Enghild JJ
J Biol Chem; 2007 Feb; 282(5):3066-76. PubMed ID: 17138567
[TBL] [Abstract][Full Text] [Related]
47. Electrochemiluminescence assay for basic carboxypeptidases: inhibition of basic carboxypeptidases and activation of thrombin-activatable fibrinolysis inhibitor.
Mao SS; Colussi D; Bailey CM; Bosserman M; Burlein C; Gardell SJ; Carroll SS
Anal Biochem; 2003 Aug; 319(1):159-70. PubMed ID: 12842119
[TBL] [Abstract][Full Text] [Related]
48. Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI).
Valnickova Z; Thaysen-Andersen M; Højrup P; Christensen T; Sanggaard KW; Kristensen T; Enghild JJ
BMC Biochem; 2009 May; 10():13. PubMed ID: 19416536
[TBL] [Abstract][Full Text] [Related]
49. Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro.
Walker JB; Hughes B; James I; Haddock P; Kluft C; Bajzar L
J Biol Chem; 2003 Mar; 278(11):8913-21. PubMed ID: 12643276
[TBL] [Abstract][Full Text] [Related]
50. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant.
Ceresa E; Van de Borne K; Peeters M; Lijnen HR; Declerck PJ; Gils A
J Biol Chem; 2006 Jun; 281(23):15878-83. PubMed ID: 16595693
[TBL] [Abstract][Full Text] [Related]
51. Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.
Sillen M; Declerck PJ
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916027
[TBL] [Abstract][Full Text] [Related]
52. Design and synthesis of conformationally restricted inhibitors of active thrombin activatable fibrinolysis inhibitor (TAFIa).
Brink M; Dahlén A; Olsson T; Polla M; Svensson T
Bioorg Med Chem; 2014 Apr; 22(7):2261-8. PubMed ID: 24588961
[TBL] [Abstract][Full Text] [Related]
53. Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.
Foley JH; Nesheim ME; Rivard GE; Brummel-Ziedins KE
Haemophilia; 2012 May; 18(3):e316-22. PubMed ID: 21933309
[TBL] [Abstract][Full Text] [Related]
54. Novel or expanding current targets in fibrinolysis.
Wyseure T; Declerck PJ
Drug Discov Today; 2014 Sep; 19(9):1476-82. PubMed ID: 24886765
[TBL] [Abstract][Full Text] [Related]
55. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.
Antovic J; Schulman S; Eelde A; Blombäck M
Haemophilia; 2001 Nov; 7(6):557-60. PubMed ID: 11851753
[TBL] [Abstract][Full Text] [Related]
56. Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis.
Vercauteren E; Gils A; Declerck PJ
Semin Thromb Hemost; 2013 Jun; 39(4):365-72. PubMed ID: 23457049
[TBL] [Abstract][Full Text] [Related]
57. Recent developments in thrombin-activatable fibrinolysis inhibitor research.
Marx PF; Verkleij CJ; Valls Seron M; Meijers JC
Mini Rev Med Chem; 2009 Sep; 9(10):1165-73. PubMed ID: 19534693
[TBL] [Abstract][Full Text] [Related]
58. Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis.
Sanglas L; Valnickova Z; Arolas JL; Pallarés I; Guevara T; Solà M; Kristensen T; Enghild JJ; Aviles FX; Gomis-Rüth FX
Mol Cell; 2008 Aug; 31(4):598-606. PubMed ID: 18722183
[TBL] [Abstract][Full Text] [Related]
59. Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis.
Bajzar L; Jain N; Wang P; Walker JB
Crit Care Med; 2004 May; 32(5 Suppl):S320-4. PubMed ID: 15118538
[TBL] [Abstract][Full Text] [Related]
60. Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins.
Semeraro F; Ammollo CT; Semeraro N; Colucci M
Haematologica; 2009 Jun; 94(6):819-26. PubMed ID: 19377079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
